By a News Reporter-Staff News Editor at Gene Therapy Weekly -- A new study on Biotechnology is now available. According to news reporting out of Memphis, Tennessee, by NewsRx editors, research stated, "Catalytic oligonucleotides, known as DNAzymes, are a new class of nucleic acid-based gene therapy that have recently been used in preclinical animal studies to treat various cancers. In this study the systemic distribution, pharmacokinetics, and safety of intravenously administered anti-MMP (matrix metalloproteinase)-9 DNAzyme (AM9D) were determined in healthy FVB and in MMTV-polyoma virus middle T (PyMT) transgenic mice bearing mammary tumors."
Our news journalists obtained a quote from the research from the University of Tennessee, "MMP-9 is known to be involved in tumor cell development, angiogenesis, invasion, and metastasis. Sulfur-35 (S-35) labeled ([S-35]-AM9D) administered intravenously, without the use of carrier molecules, to healthy and mammary tumor bearing MMTV-PyMT transgenic mice distributed to all major organs. The order of percentages of [S-35]-AM9D accumulation in different organs of healthy and MMTV-PyMT mice were blood >liver >kidney >lung >spleen >heart and mammary tumor >blood approximate to liver >kidney >spleen >lung >heart, respectively. The amount of AM9D accumulated in mammary tumors 2 hours post injection was 0.6% and 0.2% higher than in either blood or liver, respectively, and its rate of initial clearance from mammary tissue was at least 50% slower than the other organs. Approximately 43% of the delivered dosage of [S-35]-AM9D was cleared from the system via feces and urine over a period of 72 hours. No evidence of acute or chronic cytotoxicity, local or widespread, associated with AM9D treatment (up to 75mg AM9D /kg of body weight) was observed in the organs examined."
According to the news editors, the research concluded: "These data suggest that DNAzyme in general and AM9D in particular can be used systemically as a therapeutic agent to treat patients with breast cancer or other metastatic and surgically inaccessible tumors."
For more information on this research see: The Distribution, Clearance, and Safety of an Anti-MMP-9 DNAzyme in Normal and MMTV-PyMT Transgenic Mice. Nucleic Acid Therapeutics, 2013;23(6):379-388. Nucleic Acid Therapeutics can be contacted at: Mary Ann Liebert, Inc, 140 Huguenot Street, 3RD Fl, New Rochelle, NY 10801, USA. (Mary Ann Liebert, Inc. - www.liebertpub.com; Nucleic Acid Therapeutics - www.liebertpub.com/overview/nucleic-acid-therapeutics-formerly-oligonucleotides/601/)
Our news journalists report that additional information may be obtained by contacting M.A. Hallett, University of Tennessee, Center Hlth Sci, Dept. of Pharmacol, Memphis, TN 38163, United States. Additional authors for this research include P. Dalal, T.W. Sweatman and T. Pourmotabbed (see also Biotechnology).
Keywords for this news article include: Biotechnology, Memphis, Tennessee, Gene Therapy, United States, Bioengineering, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC